FindTrial
Sign In

To study the effect of diafyn in mild diabetes patients.

A study on the efficacy of tablet Diafyn in Type 2 Diabetes Mellitus – A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/02/050111
Enrollment
100
Registered
2023-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Sri Sri Institute for advanced research (SSIAR)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Newly diagnosed and those subjects on treatment of Type 2 Diabetes Mellitus 2) Age group between 25 to 55 years 3) Glycosylated hemoglobin (HbA1c) between 6.4% to 8

Exclusion criteria

Exclusion criteria: 1) Subjects with Type 1 Diabetes Mellitus 2) Subjects with established cases of Alcoholism and Drug abuse 3) Pregnant and lactating women. 4) Subjects with major renal and hepatic disorder

Design outcomes

Primary

MeasureTime frame
Values of FBS PPBS LFT HbA1C will be assessed at the end of the studyTimepoint: Baseline and end of 13 weeks.—

Secondary

MeasureTime frame
The safety of the drug will be assessed throughout the study.Timepoint: Day0,Day90.—

Countries

India

Contacts

Public ContactDr Yogeshwar Chippa

sri sri institute of advanced research

drcyogeshwar@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026